CLINICAL TRIAL: STUDY OF TAMOXIFEN AND RALOXIFENE (STAR) FOR THE PREVENTION OF B

临床试验：他莫昔芬和雷洛昔芬（STAR）预防 B 型肝炎的研究

• 批准号: 7718495
• 负责人: JOHN HARRIS WARD
• 金额: $ 0.31万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-03-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7718495
• 关键词: Adverse effects; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Disease; Funding; Grant; Health protection; Incidence; Institution; Osteoporosis prevention; Postmenopause; Prevention; Raloxifene; Randomized; Research; Research Personnel; Resources; Risk; Source; Study of Tamoxifen and Raloxifene; Tamoxifen; Thinking; Time; United States Food and Drug Administration; United States National Institutes of Health; Woman; bone; malignant breast neoplasm

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a study of postmenopausal women at increased risk for breast cancer who are randomized to either Tamoxifen or Raloxifene to determine which is most effective with the least amount of side effects. Evidence from a large clinical trial shows that tamoxifen helps to reduce the incidence of breast cancer in women who are at increased risk for developing the disease. The U.S. Food and Drug Administration (FDA) has approved tamoxifen for such use. Raloxifene has been approved by the FDA and the Canadian Health Protection Branch (HPB) for the prevention of osteoporosis (thinning of bones) in postmenopausal (women who have stopped menstruating). Researchers think raloxifene may also reduce the risk of developing breast cancer and have fewer side effects than tamoxifen. The FDA and the HPB consider the use of raloxifene for reducing the risk of breast cancer to be experimental at this time.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这是对乳腺癌风险增加的绝经后妇女的研究，这些妇女被随机分配给他莫昔芬或雷洛昔芬，以确定哪种最有效的副作用最少。 一项大型临床试验的证据表明，他莫昔芬有助于减少患疾病风险增加的女性乳腺癌的发生率。 美国食品药品监督管理局（FDA）已批准了他莫昔芬用于这种使用。 Raloxifene已获得FDA和加拿大健康保护部（HPB）的批准，用于预防绝经后（停止月经）的骨质疏松症（骨骼变薄）。 研究人员认为，雷洛昔芬还可以降低患乳腺癌的风险，而副作用比他莫昔芬更少。 FDA和HPB考虑使用雷昔芬来降低乳腺癌的风险，目前是实验性的。